Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cardiol Therapeutics (NQ: CRDL ) 1.830 -0.080 (-4.19%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 6, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Cardiol Therapeutics < Previous 1 2 3 Next > CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q2 2024 August 12, 2024 CRDL stock results show that Cardiol Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients June 17, 2024 In a phenomenal year marked by over +180% gains in its stock price, Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) added another feather to its cap last week with the announcement of its Phase II... Via TheNewswire.com Exposures Product Safety Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients June 17, 2024 Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients Via News Direct Exposures Product Safety Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis June 13, 2024 Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis painCardiolRx™ also shown to reduce... Via Newsfile Sector Spotlight: Orphan Drug Developers With Significant Upside June 03, 2024 Via AB Newswire Topics ETFs Exposures Product Safety Stocks That Hit 52-Week Lows On Wednesday October 19, 2022 On Wednesday, 200 companies hit new 52-week lows. Via Benzinga Sector Spotlight: Orphan Drug Developers With Significant Upside June 03, 2024 The biotech sector is finally beginning to recover following a two year stretch of underperformance that was largely driven by rising interest rates and other macro factors. Biotech has a track record... Via TheNewswire.com Topics ETFs Exposures Product Safety Analysts Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) May 28, 2024 Via AB Newswire Analysts’ Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics May 28, 2024 Analysts’ Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics Via News Direct CRDL Stock Earnings: Cardiol Therapeutics Meets EPS for Q1 2024 May 14, 2024 CRDL stock results show that Cardiol Therapeutics met analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In May 14, 2024 Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. Via Benzinga Topics Cannabis Exposures Cannabis CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q4 2023 April 02, 2024 CRDL stock results show that Cardiol Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. Via InvestorPlace Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis February 21, 2024 This is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 21, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)... Via Newsfile Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis February 15, 2024 This is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 15, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)... Via Newsfile Exposures Product Safety Cardiol Therapeutics - This Penny Stock Is An Analysts Favorite January 31, 2024 Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies. Via Talk Markets Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis November 01, 2023 Toronto, Ontario--(Newsfile Corp. - November 1, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a... Via Newsfile Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases October 13, 2023 Via Get News Topics Death Exposures Death Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases October 13, 2023 --News Direct-- Via News Direct Topics Death Exposures Death Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases October 13, 2023 Toronto, ON, October 13, 2013 (PlatoData via 500NewsWire) -- In the United States, heart disease accounts for a significant number of deaths every year, with cardiovascular disease being the primary... Via TheNewswire.com Topics Death Exposures Death Cardiol Therapeutics Fights Heart Inflammation With Novel Formulations October 12, 2023 697,000 people die from heart disease every year in the United States – that is one in every five deaths. Via Benzinga CBD To Treat Heart Failure? New Study Shows Its Cardioprotective Effects October 10, 2023 On Tuesday, Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) announced positive study results demonstrating that subcutaneously administered cannabidiol - the active pharmaceutical ingredient in... Via Benzinga Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction October 10, 2023 Results Demonstrate the Active Pharmaceutical Ingredient in Cardiol's Novel CRD-38 Formulation Attenuates Harmful Fat Distribution and Key Markers of Cardiac... Via Newsfile Why Murphy Canyon Acquisition Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket September 21, 2023 Gainers Near Intelligence, Inc. (NASDAQ: NIR) shares rose 34.1% to $0.2801 in pre-market trading after falling 42% on Wednesday. Near Intelligence recently named its General Counsel, Jay Angelo, to... Via Benzinga Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute Myocarditis September 19, 2023 Recruitment Accelerating and Full Patient Enrollment Anticipated to be Completed During Q3 2024, up to Six Months Ahead of Schedule Multi-Center,... Via Newsfile Sidoti's Micro-Cap Virtual May Conference May 09, 2023 Via ACCESSWIRE Stocks That Hit 52-Week Lows On Tuesday October 04, 2022 On Tuesday, 44 companies hit new 52-week lows. Via Benzinga Stocks That Hit 52-Week Lows On Tuesday October 18, 2022 During Tuesday's session, 78 companies made new 52-week lows. Via Benzinga Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America September 28, 2022 Oakville, Ontario--(Newsfile Corp. - September 28, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a... Via Newsfile Hot Debate Over Myocarditis Risk Shines Spotlight on Heart Disease July 26, 2022 Palm Beach, FL – July 26, 2022 – FinancialNewsMedia.com News Commentary – As COVID-19 vaccines for kids achieve the Centers for Disease Control and Prevention (CDC) recommendation, concern it could... Via FinancialNewsMedia Exposures COVID-19 Product Safety Air Pollution is a Global Heart and Lung Health Concern July 18, 2022 Palm Beach, FL – July 18, 2022 – FinancialNewsMedia.com News Commentary – Particulate matter or particle pollution is a significant contributor to heart and lung disease. Individuals most affected by... Via FinancialNewsMedia Topics Climate Change Emissions Energy Exposures Climate Fossil Fuels < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.